SML1179

WWL113

≥98% (HPLC)

• 同義詞: 4′-[[[Methyl[[3-(4-pyridinyl)phenyl]methyl]amino]carbonyl]oxy]-[1,1′-Biphenyl]-4-carboxylic acid ethyl ester, Ethyl 4′-((methyl(3-(pyridin-4-yl)benzyl)carbamoyl)oxy)-[1,1′-biphenyl]-4-carboxylate
• 經驗公式（希爾表示法）: C₂₉H₂₆N₂O₄
• CAS號碼: 947669-86-5
• 分子量：: 466.53
• 分類程式碼代碼: 12161501
• PubChem物質ID: 329825703
• NACRES: NA.77

屬性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: powder
• 顏色: white to beige
• 溶解度: DMSO: 10 mg/mL, clear
• 儲存溫度: 2-8°C
• SMILES 字串: CCOC(C(C=C1)=CC=C1C(C=C2)=CC=C2OC(N(C)CC3=CC(C4=CC=NC=C4)=CC=C3)=O)=O
• InChI: 1S/C29H26N2O4/c1-3-34-28(32)25-9-7-22(8-10-25)23-11-13-27(14-12-23)35-29(33)31(2)20-21-5-4-6-26(19-21)24-15-17-30-18-16-24/h4-19H,3,20H2,1-2H3
• InChI 密鑰: AKIIPHDGVCFVCC-UHFFFAOYSA-N

描述

生化／生理作用

WWL113 is an inhibitor of mouse Carboxylesterase 3 (Ces3) and human CES1 (orthologue of mCes3), serine hydrolases involved in lipolysis in addition to their activities as liver detoxification enzymes. In a recent study, hCES1 activity was found to be increased two-fold in obese individuals and patients with type 2 diabetes compared to lean subjects, and is thought to generate surplus fatty acids that can deposit ectopically in tissues. WWL113 treatment resulted in major improvement of multiple features of metabolic syndrome and ameliorated obesity-diabetes in mice with lowered levels of nonesterified free fatty acids (NEFAs), triglycerides (TGs), total cholesterol and fasted glucose as well as enhanced glucose tolerance after three weeks of treatment. WWL113 inhibits Ces3 with an IC₅₀ of 120 nM and also the closely related Ces1f with an IC₅₀ of 100 nM. WWL113 inhibits mouse recombinant Ces1, Ces1c, and Abhd6 at 10 μM.

安全資訊

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable